Cornerstones of pharma market antitrust investigation


Recently, the Antimonopoly Committee of Ukraine provided number of certain actions aimed on enabling better understanding of the stance taken by the AMCU. Their activity is directed towards a number of important issues related to commercial practices on the pharmaceutical market. The article by Svitlana Panaiotidi, State Commissioner at the Antimonopoly Committee of Ukraine, and Galyna Zagorodniuk, Partner, Head of Antitrust, Head of Life Science at DLA Piper Ukraine, provides two alternative views on certain issues: market definition, restriction of re-export provisions in the distribution agreements and retro-bonuses.

The article was originally published in the Ukrainian Journal of Business Law and is reproduced with permission.